JLK, Innovation in Emergency Brain Hemorrhage Diagnosis... Proving Global Competitiveness with Deep Learning Patent

JLK (CEO Kim Dong-min), the first medical AI listed company, announced on the 18th that it has successfully obtained a domestic technology patent for a deep learning-based intracerebral hemorrhage diagnosis device and method used in the company's stroke AI solution.

The "Deep Learning-Based Intracerebral Hemorrhage Diagnosis Device and Method" applied for by JLK was finally registered earlier this month. JLK secured this patented technology by focusing on the problem that the analysis and diagnosis speed of existing 3D medical imaging was slow, making it difficult to apply to emergency patients.

This patent is characterized by analyzing multiple CT images with a deep learning model to detect intracerebral hemorrhage lesions and reconstruct them in 3D, enabling rapid calculation of the patient's probability of intracerebral hemorrhage. It is a technology necessary for quickly establishing treatment plans in emergency situations, as it can accurately diagnose intracerebral hemorrhage using only CT images, which are cheaper and faster to capture than MRI.

Considering that the first diagnostic process medical staff perform when transporting suspected stroke patients to the hospital is to check for intracerebral hemorrhage through non-contrast CT imaging, this patented technology is expected to play an important role in achieving diagnostic innovation in emergency medical settings.

In particular, since the demand for stroke AI solutions is expected to be high in the United States, the world's largest medical market, and Japan, which is experiencing rapid aging, demand for this solution with proven core technology capabilities is also expected to be sufficient.

Kim Dong-min, CEO of JLK, emphasized, "By obtaining a domestic technology patent for the deep learning-based intracerebral hemorrhage diagnosis device and method, JLK's medical AI technology capabilities have been recognized both internally and externally, enhancing our technology defense. We will focus on expanding the supply chain through global market expansion including the United States and Japan, and creating tangible results through obtaining insurance reimbursement and distributor contracts."

Meanwhile, JLK possesses the full stroke solution "MEDIHUB STROKE," among which the intracerebral hemorrhage detection solution "JLK-ICH" and the "Non-Contrast CT Stroke AI Solution" have each successfully obtained approval from the US FDA and Japan PMDA, respectively.

This content was produced with the assistance of AI translation services.